Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 7,007 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urologic Diseases Clear all
Recruiting Phase 2 Interventional

Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD

NCT05928936
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sodium Bicarbonate, Exercise Training, Placebo
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
40 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 15, 2026, 8:24 PM EDT
Completed No phase listed Observational

Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)

NCT05200871
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy
Interventions
Not listed
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
San Francisco, California • Belmar, New Jersey • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 15, 2026, 8:24 PM EDT
Completed Early Phase 1 Interventional

Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis

NCT05705414
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Valine, EEA
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 64 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 15, 2026, 8:24 PM EDT
Completed No phase listed Observational

Delaying the Progression of Diabetic Nephropathy in Pima Indians

NCT00353600
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 8:24 PM EDT
Completed Phase 2 Interventional

Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT)

NCT00308971
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Alpha, gamma, beta, and delta (mixed) tocopherols, alpha lipoic acid, placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Portland, Maine • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2009 · Synced Oct 15, 2026, 8:24 PM EDT
Completed Phase 2 Interventional

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

NCT06272487
View directory record Official record
Conditions
High Cardiovascular Risk, Hypertension
Interventions
Zilebesiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
139
States / cities
Alexander City, Alabama • Daphne, Alabama • Foley, Alabama + 115 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 15, 2026, 8:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

An Efficacy Study of a Dietary Supplement Drink Mix for Urinary Health Improvement

NCT07453693
View directory record Official record
Conditions
UTI's
Interventions
FLUSH
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Harrison, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 15, 2026, 8:24 PM EDT
Completed Phase 1 Interventional Results available

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

NCT04306900
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6
Combination Product
Lead sponsor
Trishula Therapeutics, Inc.
Industry
Eligibility
18 Years to 110 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 15, 2026, 8:24 PM EDT
Completed Not applicable Interventional

Expanded Quantitative Urinary Culture (EQUC) vs Standard Culture (SUC) Techniques in the Clinical Care

NCT03190421
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Expanded Urinary Culture, Standard Urine Culture (SUC)
Diagnostic Test
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 15, 2026, 8:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples

NCT00001814
View directory record Official record
Conditions
Neoplastic Syndromes, Hereditary, Urologic Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 8:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Representational Intervention to Promote Preparation for End-of-life Decision Making

NCT01259011
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
the SPIRIT intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 15, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease

NCT03574363
View directory record Official record
Conditions
Chronic Kidney Diseases, Hypertension
Interventions
KBP-5074 0.25 mg tablet, KBP-5074 0.5 mg tablet
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Princeton, New Jersey • Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 15, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis

NCT01587898
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
46
States / cities
Azusa, California • Bakersfield, California • Chino, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 15, 2026, 8:24 PM EDT
Completed Phase 1 Interventional

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

NCT00426712
View directory record Official record
Conditions
Hepatitis B
Interventions
1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
40 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 15, 2026, 8:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

NCT04179630
View directory record Official record
Conditions
Impaired Renal Function
Interventions
Aldafermin (NGM282)
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 15, 2026, 8:24 PM EDT
Terminated Phase 3 Interventional

Evaluation of Sodium Bicarbonate to Reduce the Incidence of Contrast Induced Chronic Kidney Injury in Patients With Kidney Disease

NCT00930436
View directory record Official record
Conditions
Contrast Induced Kidney Injury.
Interventions
sodium bicarbonate
Drug
Lead sponsor
MD Scientific
Industry
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
17
States / cities
Kissimmee, Florida • St. Petersburg, Florida • Rome, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 15, 2026, 8:24 PM EDT
Completed Not applicable Interventional

Multidisciplinary Inpatient Palliative Care Intervention

NCT00325611
View directory record Official record
Conditions
Cerebrovascular Accident, Cancer, Coronary Arteriosclerosis, Heart Failure, Congestive, Diabetes Mellitus, Acquired Immunodeficiency Syndrome, Failure to Thrive, Pulmonary Disease, Chronic Obstructive, Dementia, Kidney Failure, Chronic, Pneumonia, Liver Failure, Renal Failure, Respiratory Failure, Stroke
Interventions
Multidisciplinary palliative care team met with patient
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 15, 2006 · Synced Oct 15, 2026, 8:24 PM EDT
Completed Phase 3 Interventional Results available

The Bladder Instillation Comparison Study

NCT02695771
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Mitomycin C, Gemcitabine
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 15, 2026, 8:24 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

NCT05525507
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Conditioning and Stem cell infusion
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 15, 2026, 8:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Using Virtual Reality to Improve Medical Training

NCT07542834
View directory record Official record
Conditions
Type 2 Diabetes (T2DM), Geriatric Syndromes, Disability Hearing, Disability Physical, Urinary Tract Infection(UTI), Delirium Confusional State
Interventions
Cinematic Virtual Reality Training, Traditional Didactic Lecture
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 15, 2026, 8:24 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pain Management in Outpatient Urologic Procedures

NCT03393364
View directory record Official record
Conditions
Urologic Diseases
Interventions
Oxycodone, Ketorolac
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 15, 2026, 8:24 PM EDT
Terminated Phase 2 Interventional

Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery

NCT00628264
View directory record Official record
Conditions
Cardiac Surgery, Coronary Artery Bypass Grafting, Valve Surgery, Kidney Injury
Interventions
AP214, Placebo
Drug
Lead sponsor
Action Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2009 · Synced Oct 15, 2026, 8:24 PM EDT
Completed Not applicable Interventional Results available

Helping Empower Liver and Kidney Patients

NCT03426787
View directory record Official record
Conditions
Hepatitis C, Chronic Kidney Diseases, Patient Education
Interventions
Decision Aid
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 15, 2026, 8:24 PM EDT
Completed Not applicable Interventional

Communicating About Choices in Transplantation

NCT01853007
View directory record Official record
Conditions
End Stage Renal Disease and Kidney Transplantation
Interventions
COACH Program
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 15, 2026, 8:24 PM EDT